Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance

Drug resistance to tyrosine kinase inhibitor (TKI) is the main obstacle for efficient treatment of epidermal growth factor receptor (EGFR)-mutant lung cancer patients. Here we design a cetuximab-capped mesoporous silica nanoparticle (MP-SiO(2) NP) as the drug carrier to specifically target EGFR-muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuetong, Huang, Hsin-Yi, Yang, Liu, Zhang, Zhanxia, Ji, Hongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858690/
https://www.ncbi.nlm.nih.gov/pubmed/27151505
http://dx.doi.org/10.1038/srep25468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858690/
https://www.ncbi.nlm.nih.gov/pubmed/27151505
http://dx.doi.org/10.1038/srep25468

Ejemplares similares